Novo Nordisk announced on September 16 a collaboration with Anthropic to test Claude Science, the company's scientific workflow platform, on concrete pharmaceutical R&D problems.
Under this collaboration, the Danish pharmaceutical company will use Anthropic's frontier models and put the Claude Science workbench to the test on specific R&D workflows, with the stated goal of speeding up the discovery and development of new drugs. The two companies will jointly tackle drug-discovery challenges identified by Novo Nordisk's scientists and computational teams, building solutions aimed at specific scientific problems and workflows that require biological reasoning.
Claude Science bundles tools like PubMed, Jupyter, and R into a single platform covering genomics, structural biology, proteomics, and cheminformatics. It's essentially Anthropic's attempt to package the work of a junior computational scientist into an AI-assisted workflow, rather than offering just a general-purpose model.
The company was already using Claude to automate clinical trial report generation, cutting patient documentation time from months to minutes. This new agreement adds to its existing AI arrangements with OpenAI and Amazon, confirming a Novo Nordisk strategy of working with multiple AI providers in parallel rather than betting on a single partner.
For Anthropic, this deal extends a pharmaceutical partnership strategy that already includes Bristol Myers Squibb, which rolled out Claude to more than 30,000 employees in May 2026. The company is positioning Claude Science as a differentiated vertical offering against its competitors' generic models, betting that industry-specific specialization — not just model size — will be the next commercial battleground.
Carlos Montiel is an enterprise AI solutions architect. He implements LLMs, Agents, RAG, and orchestrators for companies across Guatemala and Latin America. Reach out for a consultation.
Contact Carlos Montiel